 Trillium Therapeutics has two lead candidates that encourage immune cells known as macrophages to gobble up cancer cells by blocking a protein known as CD47. However, the CD47 inhibitor space is incredibly crowded. There are 10 groups developing a drug that hits the CD47 pathway. 